ACT-660602
oral CXCR3 antagonist efficacy in mice model of lung inflammation from HTS and opt J. Med. Chem. Idorsia Pharmaceuticals Ltd., Allschwil, CH
Molecules of the Month - August 2022
3 minute read
Sep. 28, 2022
ACT-660602: an Oral Chemokine Receptor CXCR3 Antagonist for Autoimmune Diseases